Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial.
Summary
In a multicenter, double-blind phase 2 trial of 241 symptomatic adults with frequent PACs, memantine reduced 24-hour PAC burden more than placebo and lowered nonsustained atrial tachyarrhythmia burden with favorable tolerability. These results validate a novel glutamatergic mechanism for atrial ectopy suppression and motivate phase 3 evaluation.
Key Findings
- Memantine produced a greater reduction in 24-hour PAC count versus placebo (between-group difference 47.1 percentage points).
- Secondary endpoints showed reduced nonsustained atrial tachycardia burden and higher responder rates (≥50% PAC reduction) with memantine.
- Favorable safety profile over 6 weeks in a double-blind, multicenter setting.
Clinical Implications
Memantine could become the first targeted pharmacotherapy for frequent symptomatic PACs, particularly for patients intolerant to or failing beta-blockers or antiarrhythmics. Larger trials should assess AF prevention, symptom relief, and safety over longer durations.
Why It Matters
First randomized evidence that NMDA receptor antagonism suppresses atrial ectopy, offering a new non–ion channel therapeutic avenue. Could alter management of symptomatic PACs and potentially reduce progression to atrial fibrillation.
Limitations
- Phase 2 study with 6-week treatment limits assessment of long-term efficacy, AF incidence, and safety.
- Specific dosing and generalizability to patients with structural heart disease or polypharmacy remain uncertain.
Future Directions
Conduct phase 3 trials powered for clinical endpoints (AF onset, symptom burden, quality of life) and longer-term safety; explore dose-response and combinations with standard antiarrhythmics.
Study Information
- Study Type
- RCT
- Research Domain
- Treatment
- Evidence Level
- II - Phase 2 randomized, double-blind, placebo-controlled trial providing moderate-to-high quality evidence.
- Study Design
- OTHER